Xilio Therapeutics Amends Shelf Registration, Updates ATM Program to $14.5M with $4.6M Already Sold
XLO sits 29% above its 52-week low of $6.465.
Summary
Xilio Therapeutics updated its universal shelf registration, reducing its At-The-Market (ATM) program to $14.5 million and disclosing $4.6 million in prior sales, indicating continued dilutive capital raising for general corporate purposes.
Key Events · Financing and Capital Events · XLO
-
Amended Universal Shelf Registration
Xilio Therapeutics filed an S-3/A for a universal shelf registration, allowing it to offer up to $250 million in various securities. This amends the S-3 filed on May 12, 2026.
-
Updated At-The-Market (ATM) Program
The ATM program capacity has been updated to $14.5 million, a reduction from the $17.22 million previously registered on May 12, 2026.
-
Prior ATM Sales Disclosed
The company disclosed that $4,596,248 of common stock has already been sold under a prior ATM program, leaving approximately $9.9 million available under the current $14.5 million ATM.
-
Potential Dilution for New Investors
The filing highlights immediate and substantial dilution of $4.21 per share for new investors if the full $14.5 million ATM is sold at the assumed price of $8.35 per share.
Analysis · XLO · Life Sciences
Xilio Therapeutics filed an amendment to its universal shelf registration, updating its At-The-Market (ATM) offering program. The total ATM capacity is now set at $14.5 million, a reduction from the $17.22 million previously registered on May 12, 2026. The company also disclosed that $4,596,248 has already been sold under a prior ATM program, leaving approximately $9.9 million available under the current ATM. This ongoing capital raise is a significant dilutive event for the company, as explicitly noted by the immediate and substantial dilution of $4.21 per share for new investors if the full $14.5 million is sold. For a life sciences company with a market capitalization of approximately $50 million, securing capital is crucial for operations and extending its cash runway, which was previously reported to extend into early 2028.
How filings like this one have moved
In the 30 days to Aug 26, 2026, 29.6% of the 2932 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.01%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, XLO was trading at $8.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.9M. The 52-week trading range was $6.47 to $16.10. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.